A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

NCT00282230 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: FK778

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]